USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Maruishi Pharmaceutical Co., Ltd.

USPTO PatentsView assignee record - 7 granted patents across 10 technology areas, active 2015–2020. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

12.1

Avg claims per patent

-60%

5-year filing velocity

The verdict

Maruishi holds 7 US patents across 10 technology areas, rank #36,337 of 50,000 tracked assignees.

#36,337
of 50,000 US assignees by volume: Top 82%
by Innovation Score (25.6/100): 12.1
avg claims per patent: -60%
filing velocity, last 5 yrs

Portfolio overview

Maruishi Pharmaceutical Co., Ltd. has been granted 7 US utility patents between 2015 and 2020, placing Maruishi Pharmaceutical Co., Ltd. at rank #36,337 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Maruishi Pharmaceutical Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Maruishi sits between Marelli Suspension Systems Italy S.p.a. (7 patents, rank #36,333) and Maslow SIX Entertainment, Inc. (7 patents, rank #36,341) - the closest US assignees by grant volume. The composite Innovation Score of 25.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 5 in the 2015–2019 window, a -60% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Maruishi Pharmaceutical Co., Ltd.'s 12.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Maruishi Pharmaceutical Co., Ltd. against peers pursuing similar technology classes.

Marelli Suspensio…

7
Margo Networks PVT

7
Marina BAY Sands…

7
Marna

7
Marvell Hispania…

7
Maserati S P A

7
Masimo Semiconduc…

7
Maslow SIX Entert…

7
Maruishi Pharmace… ◀

7

What this shows Maruishi holds 7 patents at rank #36,337, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Maruishi

By rank, the assignees closest to #36,337 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Maruishi's primary technology class.

Maruishi's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

26 Top 82% higher than 18% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Maruishi Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	14.3%
2016	1	14.3%
2017	1	14.3%
2018	2	28.6%
2020	2	28.6%

Which technologies does Maruishi Pharmaceutical Co., Ltd. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 7

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 6

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 2

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 2

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 1

C07D - HETEROCYCLIC COMPOUNDS 1

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 1

C07K - PEPTIDES 1

C23C - COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL 1

H01L - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10 1

Top 10 of 10 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#36,337

Across all tracked assignees

Innovation Score

25.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Maruishi Pharmaceutical Co., Ltd. hold?

Maruishi Pharmaceutical Co., Ltd. holds 7 US granted patents filed between 2015 and 2020, spanning 10 technology areas.

What is Maruishi Pharmaceutical Co., Ltd.'s Innovation Score?

Maruishi Pharmaceutical Co., Ltd. has an Innovation Score of 25.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Maruishi Pharmaceutical Co., Ltd. focus on?

Maruishi Pharmaceutical Co., Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 7 patents. The company has filed patents in 10 CPC subclasses total.

Is Maruishi Pharmaceutical Co., Ltd.'s patent filing rate increasing or decreasing?

Maruishi Pharmaceutical Co., Ltd.'s recent filing velocity is -60% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Maruishi Pharmaceutical Co., Ltd.'s patents?

Maruishi Pharmaceutical Co., Ltd.'s patents average 12.1 claims each. This falls within the standard range, providing solid legal coverage.

How is the Maruishi Pharmaceutical Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Maruishi's 7 grants land it in the top 82% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Maruishi ranks #36,337 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.